ReviewWorld journal of clinical oncology2021
Hepatic Langerhans cell histiocytosis: A review.
Review in World journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Hepatobiliary langerhans cell histiocytosis mimicking Caroli syndrome and recurring in a liver allograft.Frontiers in medicine · 2026Article
- Structural and functional hepatic factors as prognostic indicators in children with Langerhans cell histiocytosis.Frontiers in oncology · 2026Article
- Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.Hematology. American Society of Hematology. Education Program · 2025Review
- Beyond Hepatitis: A Rare Case of Multisystem Langerhans Cell Histiocytosis in a Child.Clinical case reports · 2025Article
- Histiocyte Society blueprint for Langerhans cell histiocytosis research: from cell-of-origin to a more comprehensive cure.Haematologica · 2025Review
- Article
- High CCR6 expression increases the risk of pediatric Langerhans cell histiocytosis.Blood science (Baltimore, Md.) · 2025Article
- Liver Transplantation for Isolated Langerhans Cell Histiocytosis in an Adult.Case reports in hematology · 2025Article
- Clinical features and treatment outcomes of liver involvement in paediatric Langerhans cell histiocytosis.BMC pediatrics · 2024Article
- Exploration of treatment in childhood Langerhans cell histiocytosis based on inflammatory and malignant symptoms: a pilot study.Orphanet journal of rare diseases · 2024Article
- Liver Langerhans cell histiocytosis in a pediatric patient: a case description and literature analysis.Quantitative imaging in medicine and surgery · 2024Article
- Liver transplantation in a child with sclerosing cholangitis due to Langerhans cell histiocytosis: a case report.Frontiers in pediatrics · 2024Article
- Current perspectives on the role of liver transplantation for Langerhans cell histiocytosis: A narrative review.World journal of gastroenterology · 2022Review
- Gut and liver involvement in pediatric hematolymphoid malignancies.World journal of gastrointestinal oncology · 2022Review
- Improvement of primary vulvar Langerhans cell histiocytosis with lenalidomide.International journal of women's dermatology · 2021Article
- Adult Langerhans Cell Histiocytosis: Solitary and Multisystemic Involvement Detected on FDG PET-CT Scan.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
- Adult Hepatic Langerhans Cell Histiocytosis: Report of Two Cases With Different Clinico-pathological Manifestations.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic Langerhans cell histiocytosis (LCH) is characterized by proliferation and accumulation of Langerhans cells in the liver, causing liver dysfunction or forming a mass lesion. The liver can be involved in isolation, or be affected along with other organs. A common clinical hepatic presentation is cholestasis with pruritis, fatigue and direct hyperbilirubinemia. In late stages, there may be hypoalbuminemia. Liver biopsy may be required for the diagnosis of hepatic LCH. Histologic finding may be diverse, including lobular Langerhans cell infiltrate with mixed inflammatory background, primary biliary cholangitis-like pattern, sclerosing cholangitis-like pattern, and even cirrhosis at later stages. Because of its non-specific injury patterns with broad differential diagnosis, establishing a diagnosis of hepatic LCH can be challenging. Hepatic LCH can easily be missed unless this diagnosis is considered at the time of biopsy interpretation. A definitive diagnosis relies on positive staining with CD1a and S100 antigen. Liver involvement is a high risk feature in LCH. The overall prognosis of hepatic LCH is poor. Treating at an early stage may improve the outcome. Systemic chemotherapy is the mainstay of treatment and liver transplantation may be offered. New molecular markers involved in pathogenesis of LCH are being explored with a potential for targeted therapy. However, further studies are needed to improve outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.